Beta-adrenoblockers: treatment principles in international clinical guidelines
Abstract
The article contains data on beta-blocker efficacy in cardiology – the results of large, randomized clinical trials, and evidence-based clinical guidelines on beta-blocker therapy.
About the Author
S. Yu. Martsevich
State Research Center for Preventive Medicine, Ministry of Health of the Russian Federation, Moscow
Russian Federation
Russian Federation
References
1. Ko DT, Hebert PR, Coffey CS, et al. β-Blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288: 351-7.
2. ACC/AHA/ACP-ACIM Guidelines for the management of patients with chronic stable angina. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JACC 2003; 41: 159-68.
3. von Arnim T, TIBBS Investigators. Medical treatment to reduce total ischemic burden: Total Ischemic Burden Bisoprolol Study (TIBBS), a mutticenter trial comparing bisoprolol and nifedipine. JACC1995; 25: 231-8.
4. Beta-blocker Heart Attack Trial Research Group (BHAT). A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 1982; 247: 1707-14.
5. Wikstrand J, Warnold I, Tuomilehto J, et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from MAPHY study. Hypertension 1991; 17: 570-88.
6. Plevan A, Lehmann G, Ndrepepa G, et al. Maintenance of sinus rythm afterelectrical cardioversion of presistent atrial fibrillation. Sotalol vs bisoprolo. Eur Heart J 2001; 22: 1504-10
7. MERIT-HF Study Group. Effect of metoprolol CR/HL in chronic heart failure: metoprolol CR/HL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.
8. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999; 353: 9-13.
9. Poldermans D, Boersma E, Bax J, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N Engl J Med 1999; 341: 1789-94.
10. Viskin S, Kitzis I, Lev E, et al. Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. JACC 1995; 25: 1327-32.
11. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
12. Task Force Members, Lopez-Sendon J, Swedberg K, et al. Expert consensus document on beta-blockers of the European Society of Cardiology. Eur Heart J 2004; 25:1341-62.
13. Ambrosioni E, Leonetti G, Pessina A, et al. Patterns of hypertension management in Italy : results of a pharmacoepidemiological survey on antihypertensive therapy. J Hypertens 2000; 18: 1691-9.
14. Марцевич С.Ю. Лечение артериальной гипертонии дигидропиридиновыми антагонистами кальция в виде монотерапии и в комбинации с бета-адреноблокаторами. РКЖ 2002; 3(35): 72-5.
15. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type II diabetes: UKPDS 39. BMJ 1998; 317: 713-20.
Review
For citations:
Martsevich S.Yu. Beta-adrenoblockers: treatment principles in international clinical guidelines. Cardiovascular Therapy and Prevention. 2005;4(4):4-9. (In Russ.)
Views:
610
Email this article 
